This protocol provides access to investigational convalescent plasma for patients in acute
care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who
are judged by a healthcare provider to be at high risk of progression to severe or
life-threatening disease. Following provision of informed consent, patients will be
transfused with 1-2 units of ABO compatible convalescent plasma obtained from an individual
who has recovered from documented infection with SARS-CoV-2 (as detailed in separate
protocol). Safety information collected will include serious adverse events judged to be
related to administration of convalescent plasma. Other information to be collected will
include patient demographics, acute care facility resource utilization (total length of stay,
days in ICU, days intubated), and survival to discharge from acute care facility.